DALLAS, Oct. 31, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PRESS RELEASE -- Kali-Extracts, Inc. (USOTC: KALY) has announced taking a next step with the investor that has recently valued KALY’s biopharmaceutical technology at $50 million. The valuation has been presented to KALY by an investor interested in acquiring KALY’s U.S. Patented Cannabis Extraction Process and associated biopharmaceutical research and developments. KALY management has asked the investor to provide a “working” term-sheet for discussion purposes. The proposed transaction has KALY maintaining rights to its Patented Cannabis Extraction Process for business pursuits other than pharmaceutical developments such as the cannabis infused beverage and candy business it currently conducts. KALY would also continue its CBD extraction business provided to hemp cultivation operations. KALY management considers the valuation consistent with Goldman Small Cap Research’s recent valuation, but management maintains a position that the valuation still does not reflect the full potential of its intellectual property. KALY management wants to stay involved in the ongoing biopharmaceutical developments even after a possible sale.
KALY’s intellectual property portfolio contains a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:
- Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;
- Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
- Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
- Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025.
In addition to KALY’s ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY’s U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration.
Since the last biopharmaceuticals strategy update, KALY has made substantial strides. KALY has since engaged with a major university to initiate a next round of evaluations and testing of its COPD treatment. The university program is anticipated to kickoff soon and the company plans to issue periodic updates as the program proceeds.
KALY has also made recent progress in advancing the development of its other treatments. The advances have been made possible by new partnerships. Announcements about the new partnerships are coming soon.